Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Regeneron's Results Clearing Up

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Filling the void between earnings announcements and the start of medical-conference season in a couple of months, Regeneron Pharmaceuticals (Nasdaq: REGN  ) and partner Bayer released intriguing new phase 2 study results for their macular degeneration treatment VEGF Trap-Eye earlier in the week.

Wet age-related macular degeneration is a disorder where part of the retina gets damaged over time, potentially leading to blindness. As companies like OSI Pharmaceuticals (Nasdaq: OSIP  ) , QLT (Nasdaq: QLTI  ) , and Genentech (NYSE: DNA  ) have shown in the past few years, even treating a small portion of patients with this condition can generate several hundred millions of dollars in annual sales for drugmakers.

The interim data that Regeneron released Tuesday showed how patients fared after 52 weeks of treatment with VEGF Trap-Eye. The drug's also in phase 3 testing against Genentech's leading macular degeneration treatment Lucentis.

For two of the patient groups on different doses of Trap-Eye, after 52 weeks of treatment, patients' vision improved by respective means of 9.0 and 5.4 letters on an eyesight chart. In its two much larger phase 3 studies, Lucentis patients experienced an 11.3 and 7.2 increase in visible letters after 52 weeks. At first glance, that makes VEGF Trap-Eye look at least somewhat comparable to Lucentis; more data will be revealed in September at a medical conference.

Regeneron is currently trading at an enterprise value of slightly more than $1 billion -- the market's estimated worth of its pipeline, its already FDA-approved drug Arcalyst, and other non-cash assets like Trap-Eye. The drug's potential for success against Lucentis and the other macular degeneration treatments on the market is a key component of Regeneron's current valuation. The company will need continued proof of Trap-Eye's comparable efficacy and safety to Lucentis in its ongoing studies to justify its market cap.

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. See all of our latest discoveries with a 30-day free trial subscription. 

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has an A+ disclosure policy.

Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 712110, ~/Articles/ArticleHandler.aspx, 10/27/2016 3:48:21 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 6 hours ago Sponsored by:
DOW 18,199.33 30.06 0.17%
S&P 500 2,139.43 -3.73 -0.17%
NASD 5,250.27 -33.13 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 4:00 PM
REGN $363.08 Down -3.85 -1.05%
Regeneron Pharmace… CAPS Rating: ****
DNA $94.97 Down +0.00 +0.00%
Genentech CAPS Rating: ****
OSIP.DL $0.00 Down +0.00 +0.00%
OSI Pharmaceutical… CAPS Rating: **
QLTI $1.90 Up +0.03 +1.60%
QLT CAPS Rating: ****